Innovative Long RNA Manufacturing for Next-Generation RNA Medicines: Join Xtalks Webinar
In the world of pharmaceuticals, the production of long RNA strands has become essential for advancing RNA-based therapeutics. As the demand for long-chain RNA, specifically sequences exceeding 100 nucleotides, continues to rise, it's crucial to explore innovative manufacturing techniques. This upcoming webinar hosted by Xtalks will delve into these advancements, showcasing a novel enzymatic ligation approach.
Participants will have the opportunity to learn about the limitations of existing methods, such as chemical synthesis and in vitro transcription, which often fall short for the production of complex long-chain RNA. For instance, current chemical synthesis methods struggle with steric hindrance issues when using certain protecting groups a necessary aspect of RNA assembly. Meanwhile, in vitro transcription typically has restrictions regarding base modifications, making it ineffective for certain RNA sequences.
The highlighted speaker, Masato Sanosaka, a renowned expert from Ajinomoto Bio-Pharma Services, will explain the new enzymatic technique that employs T4 RNA ligase 2 and complements DNA splints. This method can efficiently assemble short RNA fragments into functional long-chain RNA, significantly enhancing production capabilities. This innovative approach not only addresses the limitations of existing methods but also opens new avenues for drug discovery by enabling modifications that were previously unachievable.
The webinar will also cover real-world applications, including successful syntheses of RNA sequences with altered bases and functional protein production. Attendees will be introduced to exciting prospects for nucleic acid therapeutics that could be pivotal for conditions previously considered too complex for RNA treatment. For example, the session will feature case studies that demonstrate the synthesis of 100-mer RNAs with chemical modifications and a 560-base mRNA that produced a functional protein in a cell-free environment.
By participating in this class, professionals will gain invaluable insights into the future of RNA therapeutics, discussing critical topics such as the synthesis of nucleic acids and their therapeutic potential. Exploring advanced methodologies like enzymatic ligation will empower participants to stay at the forefront of drug development strategies.
Join us on October 21, 2025, at 10 am EDT (4 pm CEST) for this insightful event. Register now to ensure your space in this essential conversation about the future of RNA medicine and to hear directly from industry leaders. To learn more about the webinar or to register, visit the Xtalks website.
As an educator, Xtalks continues to be a leading provider of webinars and content for professionals in life sciences, healthcare, and related fields, delivering critical updates and developments that help professionals traverse the complexities of evolving markets. This event is a must-attend for anyone involved in biomedicine or RNA research who seeks to remain competitive in their field and drive the future of medical therapies forward.
Participants will have the opportunity to learn about the limitations of existing methods, such as chemical synthesis and in vitro transcription, which often fall short for the production of complex long-chain RNA. For instance, current chemical synthesis methods struggle with steric hindrance issues when using certain protecting groups a necessary aspect of RNA assembly. Meanwhile, in vitro transcription typically has restrictions regarding base modifications, making it ineffective for certain RNA sequences.
The highlighted speaker, Masato Sanosaka, a renowned expert from Ajinomoto Bio-Pharma Services, will explain the new enzymatic technique that employs T4 RNA ligase 2 and complements DNA splints. This method can efficiently assemble short RNA fragments into functional long-chain RNA, significantly enhancing production capabilities. This innovative approach not only addresses the limitations of existing methods but also opens new avenues for drug discovery by enabling modifications that were previously unachievable.
The webinar will also cover real-world applications, including successful syntheses of RNA sequences with altered bases and functional protein production. Attendees will be introduced to exciting prospects for nucleic acid therapeutics that could be pivotal for conditions previously considered too complex for RNA treatment. For example, the session will feature case studies that demonstrate the synthesis of 100-mer RNAs with chemical modifications and a 560-base mRNA that produced a functional protein in a cell-free environment.
By participating in this class, professionals will gain invaluable insights into the future of RNA therapeutics, discussing critical topics such as the synthesis of nucleic acids and their therapeutic potential. Exploring advanced methodologies like enzymatic ligation will empower participants to stay at the forefront of drug development strategies.
Join us on October 21, 2025, at 10 am EDT (4 pm CEST) for this insightful event. Register now to ensure your space in this essential conversation about the future of RNA medicine and to hear directly from industry leaders. To learn more about the webinar or to register, visit the Xtalks website.
As an educator, Xtalks continues to be a leading provider of webinars and content for professionals in life sciences, healthcare, and related fields, delivering critical updates and developments that help professionals traverse the complexities of evolving markets. This event is a must-attend for anyone involved in biomedicine or RNA research who seeks to remain competitive in their field and drive the future of medical therapies forward.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.